Calceolarioside A

Calceolarioside A is an iridoid glycoside compound that demonstrates significant antinociceptive and anti-inflammatory properties through modulation of pain and inflammatory pathways. Research shows it reduces pain responses by up to 75% and alleviates thermal hyperalgesia in preclinical studies.

Origin & History

Calceolarioside A is a phenylpropanoid glycoside isolated from several plant species, including various *Calceolaria* species, *Fraxinus insularis*, and *Aeschynanthus bracteatus*. It is typically extracted from plant methanolic extracts or callus tissues and can be synthesized chemically via organocatalysts.

Historical & Cultural Context

There are no documented traditional or historical medicinal uses for Calceolarioside A. It is primarily studied as a phytochemical isolate without noted ethnopharmacological context.

Health Benefits

• Reduces formalin-induced licking by 35% in phase 1 and 75% in phase 2 in mice, indicating antinociceptive properties (preclinical evidence).[3] • Alleviates carrageenan-induced thermal hyperalgesia in mice at 50-100 μg/paw dosage (preclinical evidence).[3] • Diminishes zymosan-induced paw edema in mice by reducing edema 1-4 hours post-administration with 50-100 μg/paw (preclinical evidence).[3] • Inhibits IL-6, TNFα, and IL-1β release from LPS-stimulated THP-1 cells in a concentration-dependent manner, showcasing anti-inflammatory effects (in vitro evidence).[3]

How It Works

Calceolarioside A exerts its antinociceptive effects by modulating nociceptive pathways involved in pain transmission, particularly targeting formalin-induced pain responses. The compound demonstrates anti-inflammatory activity by inhibiting inflammatory mediators that contribute to carrageenan-induced thermal hyperalgesia and zymosan-induced edema formation.

Scientific Research

No human clinical trials or meta-analyses have been conducted on Calceolarioside A. The existing evidence is limited to in vitro studies and animal models, such as those involving paw injection in mice demonstrating antinociceptive and anti-inflammatory effects (PMID: 35408584).[3]

Clinical Summary

Current evidence for calceolarioside A is limited to preclinical animal studies with no human clinical trials available. Mouse studies demonstrate significant antinociceptive effects, showing 35% reduction in phase 1 and 75% reduction in phase 2 formalin-induced licking responses. Additional research shows effectiveness against thermal hyperalgesia at 50-100 μg/paw dosages and reduction of paw edema in inflammation models. The evidence strength remains preliminary due to the absence of human studies.

Nutritional Profile

Calceolarioside A is a phenylpropanoid glycoside (phenylethanoid glycoside) compound, not a food ingredient or macronutrient source. It contains no meaningful macronutrients (protein, fat, or carbohydrates in a nutritional sense), fiber, or conventional vitamins/minerals. Structurally, it is composed of a caffeic acid ester linked to a glycoside backbone, contributing to its classification as a polyphenolic bioactive compound. Molecular formula: C20H22O11 (approximate molecular weight ~442 g/mol). Its bioactive profile is defined by its catechol moiety and caffeic acid component, which confer antioxidant and anti-inflammatory properties. Bioavailability data in humans is not established; preclinical studies utilized direct intraplantar administration (50–100 μg/paw in mice), bypassing oral absorption. Oral bioavailability of phenylethanoid glycosides as a class is generally limited due to hydrolysis by gut microbiota and intestinal enzymes, which may cleave the glycoside linkage and alter bioactivity. No data exists on standard nutritional concentrations, dietary intake levels, or micronutrient contributions, as this compound is studied exclusively as an isolated phytochemical in pharmacological contexts rather than as a dietary nutrient.

Preparation & Dosage

No clinically studied dosage ranges exist due to the lack of human trials. In preclinical studies, doses of 50-100 μg/paw were used for anti-hyperalgesic and anti-edema effects in mice. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Acteoside, Forsythiaside, Verbascoside

Safety & Interactions

No human safety data exists for calceolarioside A due to lack of clinical trials. Potential interactions with pain medications, NSAIDs, or anti-inflammatory drugs are unknown but theoretically possible given its mechanism of action. Pregnancy and breastfeeding safety cannot be established without human studies. Long-term safety, optimal dosing, and contraindications remain undefined pending clinical research.